(Q30647378)

English

Demyelinating Disease following Anti-TNFa Treatment: A Causal or Coincidental Association? Report of Four Cases and Review of the Literature

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

16 August 2017

Demyelinating Disease following Anti-TNFa Treatment: A Causal or Coincidental Association? Report of Four Cases and Review of the Literature (English)

1 reference

Europe PubMed Central

16 August 2017

demyelinating disease

1 reference

based on heuristic

inferred from title

author name string

E Andreadou

1

1 reference

Europe PubMed Central

16 August 2017

E Kemanetzoglou

2

1 reference

Europe PubMed Central

16 August 2017

Ch Brokalaki

3

1 reference

Europe PubMed Central

16 August 2017

M E Evangelopoulos

4

1 reference

Europe PubMed Central

16 August 2017

C Kilidireas

5

1 reference

Europe PubMed Central

16 August 2017

A Rombos

6

1 reference

Europe PubMed Central

16 August 2017

E Stamboulis

7

1 reference

Europe PubMed Central

16 August 2017

publication date

16 May 2013

1 reference

Europe PubMed Central

16 August 2017

Case Reports in Neurological Medicine

1 reference

Europe PubMed Central

16 August 2017

2013

1 reference

Europe PubMed Central

16 August 2017

671935

1 reference

Europe PubMed Central

16 August 2017

copyright license

Creative Commons Attribution 3.0 Unported

1 January 2013

1 reference

April 2022 Public Data File from Crossref

copyright status

1 reference

April 2022 Public Data File from Crossref

Treatment of TNF mediated diseases by selective inhibition of soluble TNF or TNFR1.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3670521

14 July 2018

Immune-mediated adverse effects of biologicals used in the treatment of rheumatic diseases

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3670521

14 July 2018

Neurological deficits during treatment with tumor necrosis factor-alpha antagonists

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3670521

14 July 2018

Inflammatory neurological disease in patients treated with tumor necrosis factor alpha inhibitors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3670521

14 July 2018

Tumor necrosis factor alpha (TNF-α), anti-TNF-α and demyelination revisited: an ongoing story

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3670521

14 July 2018

Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3670521

14 July 2018

Demyelinating disease in patients treated with TNF antagonists in rheumatology: data from BIOBADASER, a pharmacovigilance database, and a systematic review

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3670521

14 July 2018

TNF-α antagonists beyond approved indications: stories of success and prospects for the future.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3670521

14 July 2018

Autoimmune diseases induced by biological agents: a double-edged sword?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3670521

14 July 2018

Long-term course of demyelinating neuropathies occurring during tumor necrosis factor-alpha-blocker therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3670521

14 July 2018

Inflammatory demyelinating events following treatment with anti-tumor necrosis factor.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3670521

14 July 2018

Non-MS autoimmune demyelination

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3670521

14 July 2018

Tumor necrosis factor antagonist mechanisms of action: a comprehensive review

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3670521

14 July 2018

TNFalpha blockade in human diseases: an overview of efficacy and safety

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3670521

14 July 2018

Guillain-Barré and Miller Fisher syndromes occurring with tumor necrosis factor alpha antagonist therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3670521

14 July 2018

Adalimumab clinical efficacy is associated with rheumatoid factor and anti-cyclic citrullinated peptide antibody titer reduction: a one-year prospective study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3670521

14 July 2018

Familial risk of multiple sclerosis: a nationwide cohort study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3670521

14 July 2018

Anti-tumor necrosis factor alpha-associated multiple sclerosis.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3670521

14 July 2018

Demyelination and inhibition of tumor necrosis factor (TNF).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3670521

14 July 2018

Anti-tumour necrosis factor alpha therapy in rheumatoid arthritis: an update on safety

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3670521

14 July 2018

Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3670521

14 July 2018

Demyelinating and neurologic events reported in association with tumor necrosis factor alpha antagonism: by what mechanisms could tumor necrosis factor alpha antagonists improve rheumatoid arthritis but exacerbate multiple sclerosis?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3670521

14 July 2018

Uncoupling the proinflammatory from the immunosuppressive properties of tumor necrosis factor (TNF) at the p55 TNF receptor level: implications for pathogenesis and therapy of autoimmune demyelination

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3670521

14 July 2018

Increased peripheral T cell reactivity to microbial antigens and collagen type II in rheumatoid arthritis after treatment with soluble TNFalpha receptors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3670521

14 July 2018

On the role of tumor necrosis factor and receptors in models of multiorgan failure, rheumatoid arthritis, multiple sclerosis and inflammatory bowel disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3670521

14 July 2018

Increased MRI activity and immune activation in two multiple sclerosis patients treated with the monoclonal anti-tumor necrosis factor antibody cA2.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3670521

14 July 2018

Multiple sclerosis following etanercept treatment for ankylosing spondylitis

1 reference

https://api.crossref.org/works/10.1155%2F2013%2F671935

21 January 2018

Cerebral MRI lesions and anti-tumor necrosis factor-alpha therapy

1 reference

https://api.crossref.org/works/10.1155%2F2013%2F671935

21 January 2018

Occurrence of ankylosing spondylitis and multiple sclerosis-like syndrome in a HLA-B27 positive patient.

1 reference

https://api.crossref.org/works/10.1155%2F2013%2F671935

21 January 2018

Infliximab-associated retrobulbar optic neuritis

1 reference

https://api.crossref.org/works/10.1155%2F2013%2F671935

21 January 2018

Multiple sclerosis onset during etanercept treatment

1 reference

https://api.crossref.org/works/10.1155%2F2013%2F671935

21 January 2018

Therapeutic effect of PEGylated TNFR1-selective antagonistic mutant TNF in experimental autoimmune encephalomyelitis mice

1 reference

https://api.crossref.org/works/10.1155%2F2013%2F671935

21 January 2018

Onset of multiple sclerosis associated with anti-TNF therapy.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3670521

25 November 2018

Optic neuritis after infliximab therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/23762678

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Neurological symptoms suggestive of demyelination in Crohn's disease after infliximab therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/23762678

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Association of rheumatoid arthritis with multiple sclerosis: report of 14 cases and discussion of its significance

1 reference

https://pubmed.ncbi.nlm.nih.gov/23762678

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Autoimmune disease concomitance among inflammatory bowel disease patients in the United States, 2001-2002

1 reference

https://pubmed.ncbi.nlm.nih.gov/23762678

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

New-onset demyelination induced by infliximab therapy in two rheumatoid arthritis patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/23762678

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Successful rechallenge with anti-tumor necrosis factor alpha for psoriatic arthritis after development of demyelinating nervous system disease during initial treatment: comment on the article by Mohan et al

1 reference

https://pubmed.ncbi.nlm.nih.gov/23762678

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Update on the British Society for Rheumatology guidelines for prescribing TNFalpha blockers in adults with rheumatoid arthritis (update of previous guidelines of April 2001)

1 reference

https://pubmed.ncbi.nlm.nih.gov/23762678

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Demyelinating disease in a patient with psoriatic arthritis and family history of multiple sclerosis treated with infliximab

1 reference

https://pubmed.ncbi.nlm.nih.gov/23762678

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Towards the next generation of anti-TNF drugs

1 reference

https://pubmed.ncbi.nlm.nih.gov/23762678

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

TNF neutralization in MS: results of a randomized, placebo-controlled multicenter study. The Lenercept Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/23762678

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Demyelinating events in rheumatoid arthritis after drug exposures

1 reference

https://pubmed.ncbi.nlm.nih.gov/23762678

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Tumor necrosis factor mediates myelin and oligodendrocyte damage in vitro

1 reference

https://pubmed.ncbi.nlm.nih.gov/23762678

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Progressive multifocal leukoencephalopathy associated with immunosuppressive therapy in rheumatic diseases: Evolving role of biologic therapies

1 reference

https://pubmed.ncbi.nlm.nih.gov/23762678

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Demyelination-like syndrome in Crohn's disease after infliximab therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/23762678

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1155/2013/671935

1 reference

Europe PubMed Central

16 August 2017

1 reference

Europe PubMed Central

16 August 2017

1 reference

Europe PubMed Central

16 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q30647378&oldid=1799500435"